Upstate Active Clinical Trials Seeking Volunteers

Cancer Clinical Trials

• 5585
  A Phase I/II Study in Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer.
• 59
  A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer
• 53
  A Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (RTOG 0126)
• 52
  A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer (RTOG 0415)
• 16
  A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer (NSABP B-39 / RTOG 0413)
• 5849
  A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy
• 3811F
  Allogeneic Hematopoietic Stem Cell Transplanation for CLL, CML, AML, ALL, Myelodysplasia and Non-Hodgkin?s Lymphoma after Total Body Irradiation and Cyclophosphamide Conditioning or Cyclophosphamide and ATG Conditioning For Aplastic Anemia.
• 4130
  Allogeneic Peripheral Blood Stem Cell Transplant Utilizing Non-Myeloablative Conditioning Therapy. A Phase II Study.
• 3260
  Autologous Hematopoietic Stem Cell and/or Bone Marrow Transplantation after High Dose Chemotherapy (Carboplatinum, Etoposide) in Patients with Recurrent/Refractory Germ Cell Tumors
• 3311
  Autologous Hematopoietic Stem Cell Transplantation After Melphalan with or without Total Body Irradiation for Multiple Myeloma.
• 4429
  Autologous Stem Cell Transplantation for Acute Myeloid Leukemia in First or Second Remission.
• 5704
  AXITINIB AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
• 5731
  A Randomized Phase II Study of Three Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia
• 5501
  CALGB 10503 Phase II Study of Maintenance Therapy with Decitabine (NSC #127716, IND #50733) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML < 60 Years
• 5537
  CALGB 30504: Combination Cisplatin, Etoposide and Sunitinib Malate (IND 74019; NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/II Study
• 82
  CALGB 30607: Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
• 4745
  CALGB-40101: Cyclophosphamide and Doxorubicin (CA) (4 v. 6 cycles) versus Paclitaxel (12 weeks vs. 18 weeks) as Adjuvant Therapy for Women with Node-Negative Breast Cancer: A 2X2 Factorial Phase III Randomized Study.
• 48
  Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) For Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
• 88
  CALGB 40502: A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined With Bevacizumab as First -Line Therapy for Locally Recurrent or Metastatic Breast Cancer
• 97
  Randomized Phase III Trial of Paclitaxel Combined With Trastuzumab, Lapatinib, or Both as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer
• 24
  CALGB 50303-Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas
• 5392
  A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma.
• 5661
  A Phase II Trial of Bortezomib (NSC # 681239) + Lenalidomide (Revlamid, CC-5013) (NSC # 703813) for Relapsed/Refractory Mantel Cell Lymphoma.
• 27
  A phase III trial of Irinotecan/5-fu/Leucovorin or Oxaliplatin/5-fu/Leucovorin with Bevacizumab, or Cetuximab (c225), or with the combination of Bevacizumab and Cetuximab for subjects with untreated metastatic adenocarcinoma of the colon or rectum
• 55
  CALGB 90203:Randomized Phase III Study of Neo-adjuvant Docetaxel and Androgen Deprivation prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
• 62
  ECOG E1505:A Phase III Randomized Trial of Adjuvant Chemotherapy with or Without Bevacizumab for Patients with Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
• 5220
  Phase III Randomized Study of Four Weeks High Dose IFN-±2b in Stage T2bN0, T3a-bN0, T4a-bN0 and T1-4 N1a2a (microscopic) Melanoma
• 42
  ECOG E2805-A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
• 5039
  Genmab:Hx-CD4-110: Open-label, Dose escalation, followed by Double-blind, Randomized, Two-dose,Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody,in Patients with Mycosis Fungoides type CTCL (stage IB-IVB) who are Refractory or Intolerant to Targretin (bexarotene) and one other Standard Therapy.
• 49
  GOG 219 - A Phase III, Randomized Trial Of Weekly Cisplatin And Radiation Versus Cisplatin And Tirapazamine And Radiation In Stage IB2, IIA, IIB, IIIB And IVA Cervical Carcinoma Limited To The Pelvis
• 4165
  High Dose Cyclophosphamide, BCNU, Etoposide & Autologous Hematopoietic Stem Cell Transplantation for Resistant & Relapsed Hodgkin's Disease.
• 4160
  High Dose Cyclophosphamide, Thiotepa & Etoposide Followed by Autologous Hematopoietic Stem Cell Transplantation (Intermediate & High Grade).
• 54
  NCCTG N0147:A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer
• 77
  Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Recieving Cisplatan and Etopside.
• 5035
  Study Drug Versus Other Chemotherapeutic Agents For Third-Line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkin?s Lymphoma: A Randomized, Controlled, Phase III Comparative Trial.
• 5241
  Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients
• 47
  Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment of Breast Cancer: The TAILORx Trial
• 3805F
  ROLE of HTLVS and related endogenous sequences in autoimmune diseases and human cancers
• 75
  A RANDOMIZED PHASE III COMPARISON OF STANDARD-DOSE (60 Gy) VERSUS HIGH-DOSE (74 Gy) CONFORMAL RADIOTHERAPY WITH CONCURRENT AND CONSOLIDATION CARBOPLATIN/PACLITAXEL IN PATIENTS WITH STAGE IIIA/IIIB NON-SMALL CELL LUNG CANCER
• 5414
  S0424: Molecular Epidemiology Case Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men
• 4946
  SWOG 0220: A Phase II Trial Of Induction Chemoradiotherapy With Cisplatin/Etoposide Followed By Surgical Resection, Followed By Docetaxel, For Non-Small Cell Lung Cancer Involving The Superior Sulcus (Pancoast Tumors).

Search Again